Clinical Trials Browser

Phase 2 × Carcinoma, Hepatocellular × envafolimab × Clear all

NCT06498622 2024-07-12

Adjuvant Treatment of Patients With High Risk of Recurrent Hepatocellular Carcinoma With Donafenib in Combination With Envafolimab

Phase 2 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular